483
Medtronic NeuromodulationMedtronic Neuromodulation – FDA 483, Oct 17, 2019
Record Details
An FDA inspection of Medtronic Neuromodulation in Minneapolis revealed two significant issues. The firm failed to adequately document design input requirements for interchanging programmer applications, which led to patients experiencing excessive stimulation and pain. Additionally, procedures for corrective and preventive actions related to suppliers were not properly established, with multiple CAPAs lacking essential quality records for various phases.
View Company Profile
ID · 00137af1-6573-4e37-a715-8bd0482e134a
Other documents for Medtronic Neuromodulation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.